One of the biggest challenges with popular GLP-1 weight loss drugs like Ozempic and Mounjaro is what happens when you stop taking them. The weight often comes back. Fractyl Health thinks it has a solution, and the data it released Wednesday suggests it might be onto something.

The company reported one-year results from the Midpoint Cohort of its REMAIN-1 study, showing that a single treatment with its investigational Revita DMR System helped patients maintain more of their GLP-1-induced weight loss than a sham procedure. Investors liked what they saw: shares of Fractyl Health (GUTS) were up 19.54% at $0.85 at the time of publication.

How Revita Works

Revita is a procedural therapy that uses a catheter-based system to deliver thermal energy to the duodenum, the first part of the small intestine. The idea is that by modifying the duodenal lining, the procedure can help reset the body's metabolic response, making it easier to maintain weight loss after stopping GLP-1 drugs.

In the modified intention-to-treat population of 45 participants, Revita reduced weight regain by about 40% versus the sham procedure after one year. Patients treated with Revita experienced a least-squares mean weight regain of 7.8% of body weight, compared with 13.0% in the sham group.

But the results got even better for patients who received more extensive treatment. The company said patients who underwent duodenal ablation exceeding 14 centimeters retained about 81% of their GLP-1-induced weight loss after one year. By comparison, participants in the sham arm maintained just 48% of their weight loss. Weight regain in this subgroup was 4.8% versus 13.0% in the sham arm, representing a reduction of more than 60%.

Bigger Benefits for Higher-Risk Patients

Fractyl also highlighted results from an optimized subgroup: patients who received complete duodenal ablation and had achieved at least 17.5% weight loss during the GLP-1 run-in period. In that group, Revita preserved approximately 84% of GLP-1-induced weight loss at one year, compared with 46% in the sham arm. Least-squares mean weight regain was 4.1% for Revita recipients versus 13.5% for sham-treated participants.

According to Fractyl, these findings suggest that patients with a greater likelihood of regaining weight after stopping GLP-1 therapy may derive the greatest benefit from Revita. That makes intuitive sense: if you have more to lose, you have more to gain from a treatment that helps you keep it off.

Strong Responder Rates and Safety

The company said 73% of patients in the Midpoint Cohort's modified intention-to-treat population met the weight-maintenance responder threshold, which measures the proportion of patients maintaining at least 5% total body weight loss relative to their pre-tirzepatide weight after one year. Among participants receiving complete duodenal ablation, the responder rate increased to 91%.

Safety is always a concern with any new procedure, but the data here look clean. Fractyl reported no device- or procedure-related serious adverse events during the study. No new device-related treatment-emergent adverse events were recorded between six and 12 months. Overall treatment-emergent adverse event rates remained comparable between the Revita and sham groups at 24% and 25%, respectively.

There was also a notable metabolic signal: one participant in the sham arm received a new diagnosis of Type 2 diabetes, while no new cases were reported among Revita-treated patients. That's a small number, but it hints at potential broader metabolic benefits beyond weight maintenance.

What This Means

The GLP-1 drug market is booming, but adherence is a problem. Many patients stop taking these drugs due to side effects, cost, or simply because they've reached their goal weight. The problem is that the weight often comes back. If Fractyl can offer a one-time procedure that helps patients maintain their weight loss after stopping GLP-1s, it could carve out a significant niche.

The company is still in clinical development, and larger pivotal studies will be needed to confirm these results. But for now, the data suggest that Revita could be a game-changer for patients who want to get off GLP-1 drugs without watching the pounds pile back on.